ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3000
Abstract: 3000Background: ICOS is a costimulatory molecule expressed on the surface of activated T cells. JTX-2011 is an ICOS agonist designed to stimulate CD4 T effector (T eff) cells and deplete intratumor... read more here.
Keywords: clinical activity; icos agonist; biologic clinical; iconic biologic ... See more keywords